citalopram has been researched along with Agitation, Psychomotor in 47 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 9.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
| " The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed." | 9.22 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, CM; Mintzer, J; Mulsant, BH; Munro, CA; Newell, JA; Pawluczyk, S; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D; Weintraub, D; Yesavage, J, 2016) |
| "The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 9.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 9.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 9.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "The aim of this study was to examine the association between polymorphism in the serotonin transporter gene and citalopram effectiveness and side effects in children and adolescents with major depressive disorder (MDD) and/or anxiety disorders." | 9.12 | Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2007) |
| " citalopram induced delirium." | 7.79 | Delirium during i. v. citalopram treatment: a case report. ( Delić, M; Pregelj, P, 2013) |
| "Treatment with citalopram for agitation in AD needs to be at least 9 weeks in duration to allow sufficient time for full response." | 6.80 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2015) |
| "To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 5.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
| " The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed." | 5.22 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, CM; Mintzer, J; Mulsant, BH; Munro, CA; Newell, JA; Pawluczyk, S; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D; Weintraub, D; Yesavage, J, 2016) |
| "The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 5.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 5.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 5.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "The aim of this study was to examine the association between polymorphism in the serotonin transporter gene and citalopram effectiveness and side effects in children and adolescents with major depressive disorder (MDD) and/or anxiety disorders." | 5.12 | Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2007) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| " citalopram induced delirium." | 3.79 | Delirium during i. v. citalopram treatment: a case report. ( Delić, M; Pregelj, P, 2013) |
| "Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC)." | 2.90 | Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. ( Avramopoulos, D; Baksh, SN; Devanand, DP; Drye, LT; Ehrhardt, S; Ismail, Z; Lyketsos, CG; Mintzer, J; Munro, CA; Pollock, BG; Porsteinsson, AP; Rajji, TK; Rosenberg, PB; Schneider, LS; Shade, DM, 2019) |
| "Treatment with citalopram for agitation in AD needs to be at least 9 weeks in duration to allow sufficient time for full response." | 2.80 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2015) |
| "Citalopram treatment was associated with a larger increase in QTc interval than placebo (difference in week 3 QTc adjusting for baseline QTc: 18." | 2.79 | Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Spragg, D; Weintraub, D; Yesavage, J, 2014) |
| "The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms." | 2.77 | Citalopram for agitation in Alzheimer's disease: design and methods. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D; Yesavage, J, 2012) |
| "Somatic anxiety, psychic anxiety and psychomotor agitation as assessed using the Hamilton Depression Rating Scale (HDRS) were analysed in all trials (n = 8262); anxiety-related adverse events were analysed in trials investigating paroxetine and citalopram (n = 5712)." | 2.55 | Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. ( Emilsson, JF; Eriksson, E; Hieronymus, F; Lisinski, A; Näslund, J; Nilsson, S, 2017) |
| "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are associated with significant negative outcomes for patients and their caregivers." | 2.52 | Advancements in the treatment of agitation in Alzheimer's disease. ( Antonsdottir, IM; Keltz, M; Porsteinsson, AP; Smith, J, 2015) |
| "Citalopram was the most widely used antidepressant medication (32." | 1.62 | Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study. ( Camargos, EF; Machado, FV; Martini, LLL; Novaes, MRCG; Oliveira, LF, 2021) |
| "Linezolid was discontinued after 5 days and the patient's symptoms resolved." | 1.48 | Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations. ( Ebied, A; Khoury, A; Penny, ES; Runnstrom, M, 2018) |
| "Some residual symptoms, including restlessness, insomnia, and weight change, may help better identify patients with MDD vulnerable to relapse." | 1.46 | Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. ( Mimura, M; Sakurai, H; Suzuki, T; Uchida, H; Yoshimura, K, 2017) |
| "In the Citalopram for Agitation in Alzheimer's Disease (CitAD) randomized controlled trial, the new method identifies substantially larger groups of highly benefited patients, many of whom are missed by the standard method." | 1.46 | Characterizing Highly Benefited Patients in Randomized Clinical Trials. ( Charu, V; Drye, LT; Frangakis, CE; Lyketsos, CG; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D, 2017) |
| "The citalopram for Alzheimer's disease trial evaluated citalopram for the management for agitation in Alzheimer's disease patients." | 1.43 | A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ( Akil, A; Avramopoulos, D; Bies, RR; Devanand, DP; Lyketsos, CG; Mintzer, JE; Pollock, BG; Porsteinsson, AP; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "As a result, SSRIinduced akathisia is very frequently under-recognized." | 1.40 | A case of akathisia induced by escitalopram: case report & review of literature. ( Basu, B; De, S; Dutta, N; Gangopadhyay, T; Mandal, B; Mondal, S, 2014) |
| "Severe myoclonus and increased restlessness are hallmarks of the disorder." | 1.36 | A perfect storm in the emergency department. ( Wijdicks, EF; Yee, AH, 2010) |
| "The purpose of this study was to determine the frequency of infantile adverse events from exposure through breast-feeding to maternal citalopram therapy." | 1.32 | Frequency of infant adverse events that are associated with citalopram use during breast-feeding. ( Ito, S; Lee, A; Woo, J, 2004) |
| "Citalopram was well tolerated by 13 of the patients, and 9 had a clinically impressive response." | 1.30 | An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. ( Burgio, LD; Kirshner, MA; Mulsant, BH; Pollock, BG; Rosen, J; Shuster, K; Sweet, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.26) | 18.2507 |
| 2000's | 7 (14.89) | 29.6817 |
| 2010's | 37 (78.72) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrhardt, S | 1 |
| Porsteinsson, AP | 15 |
| Munro, CA | 11 |
| Rosenberg, PB | 12 |
| Pollock, BG | 18 |
| Devanand, DP | 13 |
| Mintzer, J | 2 |
| Rajji, TK | 2 |
| Ismail, Z | 6 |
| Schneider, LS | 15 |
| Baksh, SN | 1 |
| Drye, LT | 13 |
| Avramopoulos, D | 3 |
| Shade, DM | 11 |
| Lyketsos, CG | 14 |
| Oliveira, LF | 1 |
| Camargos, EF | 1 |
| Martini, LLL | 1 |
| Machado, FV | 1 |
| Novaes, MRCG | 1 |
| Sakurai, H | 1 |
| Suzuki, T | 1 |
| Yoshimura, K | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Charu, V | 1 |
| Rein, L | 2 |
| Shade, D | 2 |
| Frangakis, CE | 1 |
| Viscogliosi, G | 2 |
| Chiriac, IM | 2 |
| Ettorre, E | 2 |
| Näslund, J | 1 |
| Hieronymus, F | 1 |
| Emilsson, JF | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 1 |
| Eriksson, E | 1 |
| Tao, Y | 1 |
| Peters, ME | 2 |
| Mintzer, JE | 11 |
| Weintraub, D | 12 |
| Yesavage, J | 10 |
| Khoury, A | 1 |
| Runnstrom, M | 1 |
| Ebied, A | 1 |
| Penny, ES | 1 |
| Aga, VM | 1 |
| Small, GW | 2 |
| Frangakis, C | 6 |
| Marano, C | 5 |
| Meinert, CL | 5 |
| Pelton, G | 6 |
| Rabins, PV | 7 |
| Basu, B | 1 |
| Gangopadhyay, T | 1 |
| Dutta, N | 1 |
| Mandal, B | 1 |
| De, S | 1 |
| Mondal, S | 1 |
| Kotbi, N | 1 |
| Singh, A | 1 |
| Kneifati-Hayek, J | 1 |
| Odom, A | 1 |
| Alexopoulos, G | 1 |
| Underwood, BR | 1 |
| Fox, C | 1 |
| Spragg, D | 1 |
| Keltz, MA | 1 |
| Smith, JS | 1 |
| Antonsdottir, IM | 1 |
| Smith, J | 1 |
| Keltz, M | 1 |
| Vaidya, V | 1 |
| Newell, J | 2 |
| Žmuc Veranič, L | 1 |
| Pregelj, P | 2 |
| Jerin, A | 1 |
| Akil, A | 1 |
| Bies, RR | 1 |
| Yesavage, JA | 2 |
| Taylor, JL | 2 |
| Kraemer, HC | 1 |
| Friedman, L | 2 |
| Madore, M | 1 |
| Chao, SZ | 1 |
| Noda, A | 2 |
| Marano, CM | 1 |
| Mulsant, BH | 5 |
| Newell, JA | 1 |
| Pawluczyk, S | 1 |
| Wilkins, JM | 1 |
| Forester, BP | 1 |
| Ulbricht, CM | 1 |
| Dumenci, L | 1 |
| Rothschild, AJ | 1 |
| Lapane, KL | 1 |
| Lazzeroni, LC | 1 |
| Leoutsakos, JS | 1 |
| Kinoshita, LM | 1 |
| Perlow, MJ | 1 |
| Ho, T | 1 |
| Schantz, O | 1 |
| Lyketsos, C | 1 |
| Bies, R | 1 |
| Abouchedid, R | 1 |
| Ho, JH | 1 |
| Hudson, S | 1 |
| Dines, A | 1 |
| Archer, JR | 1 |
| Wood, DM | 1 |
| Dargan, PI | 1 |
| Herrmann, N | 2 |
| Kowatch, JA | 1 |
| Yee, AH | 1 |
| Wijdicks, EF | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Rochon, P | 1 |
| Delić, M | 1 |
| Emeremni, CA | 1 |
| Houck, PR | 2 |
| Mazumdar, S | 2 |
| Rosen, J | 3 |
| Lee, A | 1 |
| Woo, J | 1 |
| Ito, S | 1 |
| Sağlam, E | 1 |
| Kayir, H | 1 |
| Celik, T | 1 |
| Uzbay, T | 1 |
| Blakesley, RE | 1 |
| Huber, KA | 1 |
| Kronenberg, S | 1 |
| Apter, A | 1 |
| Brent, D | 1 |
| Schirman, S | 1 |
| Melhem, N | 1 |
| Pick, N | 1 |
| Gothelf, D | 1 |
| Carmel, M | 1 |
| Frisch, A | 1 |
| Weizman, A | 1 |
| Leblhuber, F | 1 |
| Sweet, R | 1 |
| Burgio, LD | 1 |
| Kirshner, MA | 1 |
| Shuster, K | 1 |
| Kim, KY | 1 |
| Bader, GM | 1 |
| Jones, E | 1 |
| Tariot, PN | 1 |
| Dagerman, KS | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Hsiao, JK | 1 |
| Jeste, DV | 1 |
| Katz, IR | 1 |
| Olin, JT | 1 |
| Rosenheck, RA | 1 |
| Lebowitz, B | 1 |
| Lieberman, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escitalopram for Agitation in Alzheimer's Disease[NCT03108846] | Phase 3 | 392 participants (Anticipated) | Interventional | 2018-01-03 | Recruiting | ||
| Predictors of Response to Insomnia Treatments for Gulf War Veterans[NCT03208049] | 50 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
| A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807] | Phase 3 | 186 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients[NCT01119638] | Phase 4 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 27.7 |
| Placebo and Psychosocial Intervention | 28.7 |
"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks
| Intervention | percentage moderate/marked improvement (Number) |
|---|---|
| Citalopram and Psychosocial Intervention | 40 |
| Placebo and Psychosocial Intervention | 26 |
NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 4.33 |
| Placebo and Psychosocial Intervention | 5.26 |
NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 7.8 |
| Placebo and Psychosocial Intervention | 8.0 |
5 reviews available for citalopram and Agitation, Psychomotor
| Article | Year |
|---|---|
Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2017 |
When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Topics: Aged; Alzheimer Disease; Citalopram; Female; Humans; Mental Status and Dementia Tests; Psychomotor A | 2019 |
Advancements in the treatment of agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Cannabinoid Receptor Agonists; Cannabinoids; Citalopram; Clinical Trials, Phase I | 2015 |
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.
Topics: Antipsychotic Agents; Caregivers; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Dis | 2016 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
17 trials available for citalopram and Agitation, Psychomotor
| Article | Year |
|---|---|
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Double-Blind Method; Female; Humans; Male; P | 2019 |
Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; | 2017 |
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavioral Symptoms; Citalopram; Cross-Sectiona | 2018 |
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Caregi | 2014 |
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cardiotoxicity | 2014 |
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Double-Blind Method; Female; Humans; Male; P | 2015 |
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Apolipoproteins E; Brain-Derived | 2016 |
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive A | 2015 |
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Double-Blind Method; Humans; Hypnotics and Sedatives; Outcome Assessm | 2016 |
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents, Second-Generation; Ci | 2016 |
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Female; Humans; Isomerism; Male; Psychiatric Status R | 2016 |
Citalopram for agitation in Alzheimer's disease: design and methods.
Topics: Alzheimer Disease; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Female; Follow-Up | 2012 |
A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Topics: Aged, 80 and over; Citalopram; Dementia; Double-Blind Method; Female; Humans; Male; Psychiatric Stat | 2013 |
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Topics: Aged, 80 and over; Antipsychotic Agents; Citalopram; Dementia; Double-Blind Method; Female; Hospital | 2007 |
Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Citalopram; Depressi | 2007 |
[Citalopram in treatment of behavioral disorders in demented patients].
Topics: Affective Symptoms; Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Dementia; Double-Blind M | 1994 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
25 other studies available for citalopram and Agitation, Psychomotor
| Article | Year |
|---|---|
Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; | 2021 |
Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Disorders of Excessive Somnole | 2017 |
Characterizing Highly Benefited Patients in Randomized Clinical Trials.
Topics: Alzheimer Disease; Citalopram; Humans; Physicians; Psychomotor Agitation; Randomized Controlled Tria | 2017 |
Efficacy and Safety of Citalopram Compared With Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Citalopram; Delirium; Humans; Nursing Homes; Psychomotor Ag | 2018 |
Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations.
Topics: Aged; Anti-Anxiety Agents; Anti-Bacterial Agents; Citalopram; Diagnosis, Differential; Drug Interact | 2018 |
Commentary on "When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram".
Topics: Alzheimer Disease; Anxiety; Citalopram; Dementia; Humans; Psychomotor Agitation | 2019 |
Treating dementia and agitation.
Topics: Alzheimer Disease; Citalopram; Female; Humans; Male; Psychomotor Agitation; Selective Serotonin Reup | 2014 |
A case of akathisia induced by escitalopram: case report & review of literature.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Breast Neoplasms; Citalopram; | 2014 |
Citalopram in agitated and delusional demented patients who failed treatment with antipsychotic agents.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Delus | 2014 |
Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects.
Topics: Alzheimer Disease; Citalopram; Female; Humans; Male; Psychomotor Agitation; Selective Serotonin Reup | 2014 |
Calming Alzheimer's agitation: a promising drug.
Topics: Activities of Daily Living; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalopram; | 2014 |
Role of citalopram in the treatment of agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Humans; Multicenter Studies as Topic; Psychomotor Agitation; Randomiz | 2014 |
Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents, Second-Generation; Ci | 2016 |
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Alzheimer Disease; Antidepressive Agents; Citalopram; Do | 2016 |
Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Female; Hum | 2016 |
Principal components analysis of agitation outcomes in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Humans; Principal Component Analysis; Psychiatric Status Rating Scale | 2016 |
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Topics: Adamantane; Administration, Intravenous; Anti-Anxiety Agents; Cannabinoid Receptor Agonists; Citalop | 2016 |
Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram.
Topics: Aggression; Alzheimer Disease; Citalopram; Humans; Psychomotor Agitation | 2016 |
Antipsychotics and the elderly.
Topics: Aged; Antidepressive Agents, Second-Generation; Centers for Medicare and Medicaid Services, U.S.; Ci | 2009 |
A perfect storm in the emergency department.
Topics: Aged; Alzheimer Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Iatrogenic Disease; | 2010 |
Delirium during i. v. citalopram treatment: a case report.
Topics: Aged; Aggression; Citalopram; Delirium; Delusions; Depressive Disorder, Major; Humans; Injections, I | 2013 |
Frequency of infant adverse events that are associated with citalopram use during breast-feeding.
Topics: Adult; Antidepressive Agents, Second-Generation; Breast Feeding; Case-Control Studies; Citalopram; C | 2004 |
Effects of escitalopram on ethanol withdrawal syndrome in rats.
Topics: Alcohol Drinking; Animals; Antidepressive Agents; Central Nervous System Depressants; Citalopram; Do | 2006 |
An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Biological Availability; Citalopram; Female; | 1997 |
Citalopram for verbal agitation in patients with dementia.
Topics: Citalopram; Dementia; Humans; Long-Term Care; Male; Middle Aged; Psychomotor Agitation; Selective Se | 2000 |